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ABSTRACT
The treatment of breast cancer diagnosed during preg-
nancy presents a challenging situation for the patient,
family, and caregivers. Case series have demonstrated
theefficacyandsafetyofusinganthracycline-basedche-
motherapy during the second and third trimesters. Ad-
ditionally, patients should be seen, evaluated, and
treatedinamultidisciplinarysettingwithfacilitatedcom-
munication among the medical oncologist, surgical oncol-
ogist, obstetrician, radiation oncologist, pathologist, and
radiologist. This review details the available data regard-
ing the diagnosis and management of the pregnant breast
cancer patient. The Oncologist 2010;15:1238–1247
INTRODUCTION
A simultaneous diagnosis of breast cancer during preg-
nancy adds complexity to cancer treatment recommenda-
tions. However, available data demonstrate that the
pregnant breast cancer patient can receive timely standard
therapiesinamultidisciplinaryenvironmentwithamedical
oncologist, surgical oncologist, radiation oncologist, and
maternal–fetal medicine specialist participating in her care.
Much of these data are retrospective in nature, from case
reports and small case series. However, because more
women are delaying childbirth, the incidence of breast can-
cer diagnosed during pregnancy, and women choosing
treatmentduringpregnancyratherthanterminationofpreg-
nancy or treatment delays, is expected to increase. This re-
view evaluates the available data to help guide patients and
caregivers when developing treatment plans for women di-
agnosed with breast cancer during pregnancy.
EPIDEMIOLOGY
There are several estimates of the frequency of breast can-
cer diagnosed during pregnancy. Smith et al. [1] report,
from the California Obstetrics registry for 1992–1997, that
the incidence is 13 cases per 100,000 live births. This reg-
istry, however, tracks pregnancies that went on to delivery
andthereforemayunderestimateincidenceifwomenchose
to terminate a pregnancy. The Surveillance Epidemiology
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women aged 44 years is 215.8 per 100,000 [2]. Because
women delay childbirth into their third and fourth decades
[3,4],theincidenceofbreastcancerdiagnosedduringpreg-
nancyandintheimmediatepostpartumperiodappearstobe
increasing.AstudyfromtheSwedishNationalHealthReg-
istry demonstrated that the incidence of pregnancy-associ-
ated breast cancer (PABC), which encompasses diagnoses
during pregnancy and within 1 year postpartum, increased
between 1963 and 2002 from 16.0 to 37.4 per 100,000 de-
liveries [5].
DIAGNOSIS AND STAGING OF BREAST CANCER
DURING PREGNANCY
Pregnancy causes multiple changes within the breast, in-
cluding increased glandularity, size, and density of the
breast tissue, which may obscure a mass [6]. Masses may
also be assumed to be related to the pregnancy; however, in
a pregnant patient, a new palpable mass that does not re-
solve within 2 weeks should be investigated further [7].
Imaging
Mammography has been successfully used during preg-
nancy, when done with proper fetal shielding. The fetal ra-
diation exposure is estimated to be 0.4 mrad, which is less
than the 5 rad level known to be associated with fetal mal-
formations [8–10]. However, the increased density of the
breast during pregnancy may lower the sensitivity of mam-
mography. Ultrasonography is an attractive choice because
there is no radiation exposure risk for the fetus and it is able
to distinguish solid from cystic structures. Yang and col-
leagues were successfully able to identify 100% of breast
masses and axillary masses in 18 of 20 women diagnosed
with breast cancer during pregnancy [11]. Breast magnetic
resonance imaging (MRI) requires the use of gadolinium
for best imaging of the breast. There have been studies in
animal models showing that gadolinium crosses the pla-
centa and is associated with fetal abnormalities [12]. How-
ever, there are emerging, but scant, data on the safe use of
gadolinium during pregnancy for nonbreast MRI [13–15].
Until more safety data are available, the use of gadolin-
ium-enhanced MRI should be reserved until after delivery.
The interpretation of breast MRI during pregnancy may
also be problematic. Imaging of the breast mass should in-
clude tumor measurements and nodal basin evaluations as
well as clip placement at the time of biopsy if the patient is
going to receive preoperative chemotherapy.
Biopsy
Imaging and biopsies can be performed at a single session
as appropriate. Although there has been a case report of a
milk fistula with core needle biopsy [16], Dominici et al.
[17] reported on 67 patients with a diagnosis of breast can-
cerduringpregnancy,35ofwhomhadcoreneedlebiopsies
with no complications. It is important for the pathologist to
beawarethatthebiopsyspecimenisfromapregnantbreast.
Asinnonpregnantpatients,estrogenreceptor,progesterone
receptor, and human epidermal growth factor receptor
(HER)-2 should be assessed. The stage of disease and tu-
mor characteristics guide the treatment plan.
Staging Evaluations During Pregnancy
Obtaining maximal information about disease extent in the
mother while limiting fetal exposure to radiation is the goal
whenchoosingstagingevaluations.Acompletehistoryand
physical examination, CBC, and comprehensive metabolic
panel should be done prior to initiating therapy. Consider-
ation of an echocardiogram prior to anthracycline-based
chemotherapyiswarranted.Becausethemajorsitesofmet-
astatic disease are bone, lung, and liver, guidelines have
beenestablishedfororderingliverultrasound,MRIwithout
contrast of the spine, and chest x-ray with fetal shielding to
evaluate for metastatic disease in women with suspected
stage II or greater cancers [7]. Computed Tomography
scansandbonescansarenotrecommendedforroutinestag-
ing studies in the pregnant patient because of concerns of
fetal radiation exposure. Sites concerning for metastatic
disease should be biopsied whenever possible and safe to
confirm distant metastases.
An evaluation of the fetus should be made by an obste-
trician prior to initiation of therapy. Additional ultrasounds
to evaluate fetal growth, amniotic fluid, and placental func-
tion should be done at regular intervals if the patient is re-
ceiving chemotherapy.
LOCOREGIONAL THERAPY
Surgery During Pregnancy
Several case series have evaluated the risk to the fetus dur-
ing surgery. Mazze and Källén reported that when any sur-
gicalinterventionwascompletedin5,406pregnantwomen,
the observed risk for fetal malformation was not greater
than in 720,000 nonpregnant controls [18]. A higher inci-
dence of low birth weight in this population was attributed
to the underlying cause of the emergency surgery during
pregnancy. Duncan et al. [19] reported on 2,565 women
who underwent surgery during pregnancy. They demon-
strated that the incidence of fetal abnormalities was not
higher than in pregnant women who did not undergo
surgery.
Dominici et al. [17] reported on 67 women who were
diagnosed with breast cancer during pregnancy at The Uni-
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women received chemotherapy during pregnancy; 45% re-
ceived preoperative chemotherapy. Forty-seven women
underwent mastectomy and 20 underwent breast-conserv-
ingtherapy.Ofthese67women,sixhadpostoperativecom-
plications,allofwhichweremanagedasanoutpatient.Four
women had had a modified radical mastectomy and were
treated for postoperative cellulitis. Of the two women who
underwent segmental mastectomies, one had an axillary
abscess and the other had a postoperative hematoma. The
authors concluded that both mastectomy and breast-con-
serving surgery were feasible with minimal postoperative
complications.
Recently, Cardonick et al. [20] reported their series of
women who participated in a voluntary registry of PABC
patients. One hundred thirty were diagnosed with breast
cancer during pregnancy. Ninety-five women underwent
surgery during pregnancy—38 in the first trimester, 48 in
the second trimester, and nine in the third trimester. Fifty-
four women had a mastectomy, 34 had a lumpectomy, and
15 had an excisional biopsy with no further surgery. Three
of the patients miscarried after first trimester surgery (7%).
Postoperative complications were not described.
Limited data exist regarding the use of sentinel lymph
nodebiopsiesduringpregnancy.IntheM.D.Andersonsur-
gical cohort, it was noted that sentinel lymph node biopsy
was done in three women during pregnancy. There were no
noted complications [17, 21]. The estimated radiation ex-
posure to the fetus with the use of technetium is low at 4.3
mGy [21]. There is some concern regarding the use of the
isosulfanbluedyebecauseofunknownfetaleffectsandthe
risk for anaphylaxis for the patient [22]. However, anaphy-
lactic risk has been significantly decreased since the addi-
tion of preprocedure steroid use [23]. Cardonick et al. [20]
described sentinel lymph node biopsy in 30 patients, most
of whom did not receive isosulfan blue dye. Of this group,
two of the patients who had the procedure in the first tri-
mester had a miscarriage and three children had a low birth
weight. Two children had congenital malformations,
asymptomaticpulmonaryarteryfistula,andhydrocephalus,
but they had other drug exposures during the pregnancy.
More safety data on sentinel lymph node biopsies are war-
ranted prior to making this a recommended procedure dur-
ing pregnancy.
Radiation Therapy
Recommendationsfortheuseofradiationtherapyshould
be done as per guidelines based on the patient’s stage of
diseaseandtumorcharacteristics.Radiationduringpreg-
nancy risks exposure of the fetus to the radiation field
[10]. Because surgery and the initiation of systemic ther-
apies are often completed prior to the initiation of radia-
tion, radiation therapy can be delayed until after
delivery.
SYSTEMIC THERAPIES
Chemotherapy
The decision to use chemotherapy in a pregnant breast can-
cer patient should depend upon the patient’s disease stage
and tumor characteristics. Generally these are the same in-
dications as in a nonpregnant breast cancer patient. Most
chemotherapy agents are rated pregnancy category D (Ta-
ble 1). Because treating cancer during pregnancy is a rela-
tively rare situation, the available data are limited and
consist of case reports, case series, and retrospective regis-
tries, and there can be no account or knowledge of unre-
ported cases. From the data that are available, emerging
trends in the systemic treatment of breast cancer during
pregnancy are reviewed.
Reportsoffetalmalformationshavebeenintherangeof
14%–19% when chemotherapy has been given in the first
trimester. The reported frequency decreases to 1.3% during
the second and third trimesters [24]. Cardonick et al. [20]
described 130 women diagnosed with breast cancer during
pregnancy. Of these, 104 received chemotherapy during
Table 1. U.S. Food and Drug Administration pregnancy category definitions
A Controlled studies in women fail to demonstrate a risk to the fetus in the first trimester, and the possibility of fetal harm
appears remote.
B Animal studies do not indicate a risk to the fetus and there are no controlled human studies or animal studies to show an
adverse effect on the fetus, but well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus.
C Studies have shown that the drug exerts animal teratogenic or embryocidal effects, but there are no controlled studies in
women or no studies are available in either animals or women.
D Positive evidence of human fetal risk exists, but benefits in certain situations (e.g., life-threatening situations or serious
diseases for which safer drugs cannot be used or are ineffective) may make use of the drug acceptable despite its risks.
X Studies in animals or humans have demonstrated fetal abnormalities or there is evidence of fetal risk based on human
experience, or both, and the risk clearly outweighs any positive benefit.
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3.8%,whichwasnothigherthanthatreportedinthegeneral
population. Chemotherapy is typically administered with-
outdosemodificationsinthepregnantwomanandadjusted
and dosed per actual weight and body surface area [25, 26].
Anthracyclines
Multiple case series report the use of anthracycline-based
chemotherapy during the second and third trimesters of
pregnancy. The M.D. Anderson Cancer Center has been
prospectivelytreatingwomendiagnosedwithbreastcancer
during pregnancy with a standardized protocol of 5-flu-
orouracil(500mg/m
2i.v.ondays1and4),doxorubicin(50
mg/m
2givenbycontinuousinfusionover72hours),andcy-
clophosphamide (500 mg/m
2 given i.v. on day 1) the FAC
regimen,since1989[26,27].Premedicationsincludedexa-
methasone,lorazepam,andondansetronfornauseacontrol.
Hahn et al. [26] reported on 57 women treated up to 2006,
and the median number of FAC cycles given during preg-
nancy was four (range, 1–6). The mean gestational age at
deliverywasreportedas37weeks.Chemotherapywasheld
after the 35th week in order to avoid a hematologic nadir at
thetimeofdelivery.Allthewomenhadlivebirths.Oneim-
mediate maternal postpartum death was reported, resulting
from the complication of a pulmonary embolus after a ce-
sareandelivery.Ofthechildren,threehadreportedcongen-
ital malformations. One neonate was born with Down
syndrome, one was born with ureteral reflux, and a third
was born with club foot.
Cardonick et al. [20] reported, from their registry co-
hort, on 104 women who received chemotherapy during
pregnancy at a mean gestational age of 20.4  5.4 weeks.
Sixty-nine percent received an anthracycline and cyclo-
phosphamide, but the dosing schedule and dosages were
not described. Other regimens included FAC or 5-fluoro-
uracil, epirubicin, and cyclophosphamide, and several in-
cluded taxanes. Toxicity data collected showed very
limited chemotherapy side effects, with the most common
being neutropenia (n  5), mouth ulcers (n  3), and con-
stipation,tachycardia,anaphylaxis,andcellulitisofthearm
(eachwithn2).Fetalcomplicationsincludedintrauterine
growth retardation (IUGR) in eight neonates, pulmonary
complications at birth in five neonates, hyperbilirubinemia
in three neonates, and placental complications in two preg-
nancies, and one child developed a severe autoimmune dis-
order and died at 13 months.
Other series include a French National Survey that ret-
rospectively identified 20 women treated for breast cancer
with chemotherapy during pregnancy. No consistent che-
motherapy regimen was used. Two women received che-
motherapy during the first trimester and both had a
spontaneous abortion. Another neonate died at 8 days with-
outthecauseofdeathbeingdetermined[28].VanCalsteren
et al. [29] reported on 215 pregnant cancer patients, 99 of
whom had breast cancer. Although there were no reported
congenital malformations, there was a high rate of neonatal
complications resulting from early delivery. Deliveries
were induced in 71.7% of cases and 54.2% of deliveries
werepretermintheentirecohort.Miretal.[30]reportedon
a literature search of 50 women who received epirubicin-
based chemotherapy during pregnancy. Two of the three
women treated during the first trimester had a spontaneous
abortion, and three of the 47 women treated during the sec-
ond and third trimesters had complications, including sig-
nificant fetal complications.
Ring et al. [31] evaluated 28 women for breast cancer dur-
ingpregnancy:24receivedchemotherapyforearlybreastcan-
cer and four received chemotherapy for metastatic cancer.
Twelve of the women received cyclophosphamide, metho-
trexate, and 5-fluorouracil, with one spontaneous abortion.
The remaining patients received anthracycline-based chemo-
therapy. Given that methotrexate is a known abortifacient, its
use is contraindicated during pregnancy. Complications in-
cluded IUGR and placental insufficiency, and two newborns
experienced neonatal respiratory distress [31].
Taxanes
Use of taxanes (paclitaxel and docetaxel) during pregnancy
has been described in several case series that include pa-
tients with breast and gynecological cancers. Often, the use
oftaxanesisdelayeduntilafterdeliverybecausetheanthra-
cycline portion of the chemotherapy is frequently initiated
during pregnancy as a result of more published experience
with anthracyclines. Mir et al. [32] published a systematic
review of the use of taxanes during pregnancy. They were
able to identify taxane use in 40 patients. Of these, 21 re-
ceivedpaclitaxel,16receiveddocetaxel,andthreereceived
both.Therewerenoreportedcongenitalmalformations,ex-
cept for the possibility of pyloric stenosis in one infant who
had been exposed to multiple chemotherapeutic agents
[20]. There were no intrauterine deaths.
Concern of the effectiveness of taxanes during preg-
nancy has been raised because the cytochrome P-450 sys-
temisupregulatedby50%–100%duringthethirdtrimester
of pregnancy, thus potentially increasing drug metabolism
[33]. Additionally, Lycette et al. [34] reported a case in
which pharmacokinetics were measured during pregnancy
and showed a lower peak paclitaxel concentration and total
exposure than in historical controls.
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Trastuzumab therapy is standard care for women with
HER-2/neu overexpressing breast cancers. To date, there
have been 11 case reports of its use during pregnancy [35–
44].Insevenofthese,trastuzumabwasgivenformetastatic
breast cancer, whereas two women had stage II cancer and
one had stage III disease. No stage was identified in one
woman who became pregnant during the year of mainte-
nance trastuzumab and tamoxifen. Five of the pregnancies
were found to have oligohydramnios and two had anhydr-
amnios. Two of the fetuses were found to have renal dys-
function.Fourpregnancieshadnocomplicationsidentified.
One of the newborns developed respiratory failure, capil-
lary leak syndrome, and enterocolitis and died from multi-
organ failure at 21 weeks old [43]. Given the concern for
oligo- and anhydramnios, trastuzumab therapy should be
delayed until after delivery.
There has been only one report of lapatinib exposure in
a woman who conceived while on lapatinib [45]. Lapatinib
was discontinued after the first 11 weeks of pregnancy and
the delivery was uncomplicated with a healthy newborn.
Given the lack of data for lapatinib, its use is not recom-
mended until after delivery.
Endocrine Therapy
Tamoxifen therapy is not recommended during pregnancy
because it has been associated with birth defects. Although
several case reports exist with tamoxifen exposure and
healthy neonatal outcomes [46], it has also been associated
with malformations in up to 20% of exposures, including
Goldenhar’s syndrome [47], ambiguous genitalia, vaginal
bleeding, and spontaneous abortion [48–50]. Aromatase
Inhibitors are contraindicated as single-agent endocrine
therapy in premenopausal women.
Supportive Medications
Antiemeticagents,suchasondansetronandgranisetron,are
ratedaspregnancyriskfactorBandshouldbeusedtoman-
age nausea in pregnant women receiving chemotherapy.
Dexamethasonecanalsobeusedforanthracyclinepremed-
ication for nausea prophylaxis [26]. For neutropenia pro-
phylaxis, there are no randomized trials evaluating the
usage of G-CSF in pregnant breast cancer patients. How-
ever, G-CSF has been used to treat neonatal neutropenia
and/orsepsis[51,52]anditsuseduringpregnancyhasbeen
reported [53]. There are no available data regarding pegfil-
gastrim in pregnancy.
PROGNOSIS
Several case series describe outcomes in pregnant patients.
Conflicting conclusions may be the result of the reports in-
cluding PABC patients diagnosed both during and within 1
year after delivery. Advanced stages of diagnosis as well as
delaysintreatmentinitiationmayinfluencetheoutcomesof
these analyses as well. Ribeiro et al. [54] detailed worse
outcomesin178womenwithPABC,121diagnosedduring
pregnancy.Mostwomeninthatseriesdelayedtherapyuntil
after delivery and there was no information regarding che-
motherapy given during pregnancy. Tretli et al. [55] re-
ported on 35 women diagnosed with PABC, 20 of whom
were pregnant at the time of diagnosis. They were com-
pared with nonpregnant women randomly assigned with
twosetsofcontrols.Theestimatewasa3.1higherriskfor
deathinthePABCcohort.However,thereisnodescription
of the treatment received or treatment delay in these pa-
tients.Bonnieretal.[56]evaluated154womenwithPABC
in a retrospective multicenter trial and compared them with
non-PABC patients. They found that pregnancy was an ad-
verseprognosticfactor.However,inthatseries,chemother-
apy was given to only 63.6% of the PABC patients, and the
dosages, schedules, and delays in treatment initiation were
not detailed.
More recent case series have described no significant
difference. Beadle et al. [57] evaluated 652 women diag-
nosed with breast cancer at age 35 years who were either
pregnantatthetimeofdiagnosisordiagnosedwithin1year
postpartum. There was no difference in locoregional recur-
rence, distant metastasis, or overall survival when com-
pared with non-PABC controls. A Saudi-Arabian study
evaluated 28 pregnant breast cancer patients matched by
age and stage to nonpregnant controls and no difference in
termsofrelapse-freeoroverallsurvivalwasidentified[58].
Other studies from Japan, Canada, and New Zealand also
showed no differences in outcomes [6, 59, 60]. At the 2010
American Society of Clinical Oncology Annual Meeting,
Murphy et al. [61] reported on 99 patients with PABC
matched1:2withnonpregnantbreastcancerpatientsbyage
at diagnosis and year of diagnosis. Of these, 36 were diag-
nosed during pregnancy and the rest were diagnosed within
1yearafterdelivery.TheyfoundthatthePABCtumorshad
worsebiologicalfeatures,suchasstage,grade,andahigher
percentage of hormone receptor negativity; however,
PABC was not found to be an independent predictor of
worse overall survival on multivariate analysis. Therefore,
when women receive timely standard therapy regimens
there appears to be no significant difference in outcomes.
OUTCOMES IN THE CHILDREN EXPOSED TO
CHEMOTHERAPY IN UTERO
Data on long-term outcomes in children exposed to chemo-
therapy in utero for breast cancer are very limited. Hahn et
1242 Breast Cancer and Pregnancyal. [26] described 57 children exposed in utero to chemo-
therapy. Ten percent of these deliveries were complicated
by reversible breathing difficulties in the newborns. One
child developed a subarachnoid hemorrhage 2 days post-
partum and recovered. One child had Down syndrome and
two children had congenital malformations (bilateral ure-
teral reflux and club foot). At the time of the administration
of the health survey, the ages of the children were in the
range of 2–157 months, and overall all the children were
doing well, with only two of them requiring special educa-
tional needs.
Cardonick et al. [20] reported from their voluntary reg-
istryof113womenwhocontinuedtheirpregnancy,andthe
meangestationalageatdeliverywas36weeks.Eightofthe
women delivered infants with birth weights 10% for ges-
tational age. There were pregnancy complications in 19 of
the patients and a malformation rate of 3.8%, not signifi-
cantly different from that in the general population [62].
Queisser-Luft et al. [62] estimated the rate of general con-
genitalmalformationstobe6.9%inaGermanbirthregistry
for 1990–1998. Follow-up for 93 of the children was pro-
videdbythetreatingpediatricians,withamedianageatfol-
low-up of 41.8 months. Medical issues included speech
delay in two children, gastrointestinal reflux, pneumonia,
corneal abrasion, and IgA deficiency.
Additional long-term outcomes of children exposed to
chemotherapy in utero were provided by Avilés et al. [63,
64], who followed 84 children whose mothers were given
chemotherapy during pregnancy for a hematologic malig-
nancy. They reported no significant cardiac, physical, neu-
rologic,orpsychologicalabnormalities.Reynosoetal.[65]
described seven cases of eight children (one twin preg-
nancy) exposed to chemotherapy in utero for acute leuke-
mia. One child in the twin pregnancy was born with
multiple congenital abnormalities and eventually devel-
oped thyroid cancer and neuroblastoma. The remaining
children had no reported abnormalities.
Recently, Zoccarato et al. [66] reported on a retrospec-
tive multicenter trial of 30 patients diagnosed with cancer
during pregnancy, with 27 women who continued their
pregnancy. Fifty-nine percent had cesarean deliveries, with
63% of the neonates with a low birth weight resulting from
premature delivery. No excess in congenital malformations
was noted.
Table 2 Review of effects of pregnancy in BRCA mutations carriers
Study Study type n
Significant findings: risk of
developing breast cancer
Jernström et al. (1999) [74] Matched case–control 236 cases, 236 controls;
189 BRCA1 cases, 47
BRCA2 cases
Each pregnancy increases cancer
incidence in BRCA carriers aged
40 yrs.
Tryggvadóttir et al. (2002) [77] Matched case–control 100 BRCA2 carriers, 361
BRCA2
, 1,000 matched
controls
Trends toward higher risk for breast
cancer with pregnancy and breast
feeding in BRCA2 carriers.
Jernström et al. (2004) [78] Matched case–control 685 BRCA1 cases, 280
BRCA2 cases, 965
controls
Breast feeding for 1 yr for BRCA1
carriers: OR, 0.55; 95% CI, 0.38–
0.99. No breast cancer risk
reduction for breast feeding in
BRCA2 carriers.
Cullinane et al. (2005) [75] Matched case–control 934 BRCA1 cases, 326
BRCA2 cases, 1,260
controls
BRCA1 mutation and 4 children:
OR, 0.62; 95% CI, 0.41–0.94.
BRCA2 mutation with 2 children:
OR, 1.53; 95% CI, 1.01–1.36.
Greatest risk during 2-yr period
after delivery.
Antoniou et al. (2006) [71] Retrospective cohort 457 mutation carriers with
cancer and 332 mutation
carriers without cancer
Age at first birth 30 yrs in BRCA
2 carriers: HR, 4.77; 95% CI, 2.08–
10.94.
Andrieu et al. (2006) [72] Retrospective cohort 1,187 BRCA1 carriers,
414 BRCA2 carriers
Age at first birth 30 yrs in BRCA2
carriers: HR, 1.97; 95% CI, 0.67–
5.81.
Kotsopoulos et al. (2007)
[76]
Matched case–control 1,405 BRCA1 carriers,
411 BRCA2 carriers
Early first birth did not confer
protection in BRCA mutation
carriers: OR, 1.00; 95% CI,
0.98–1.03.
Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio.
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Termination of the Pregnancy
The decision to terminate a pregnancy during breast cancer
is a highly personal decision to be made by an informed
woman.Awomanmaybeadvisedtoterminateapregnancy
if it is felt that her life expectancy may not be longer than
gestation, and historically it was often assumed that termi-
nation was warranted in all cases. One recent series de-
scribed 30 of 130 patients who were advised to terminate
their pregnancy. These recommendations did not change
significantly between 1996 and 2003, but more recently the
frequency of the recommendation for termination has been
decreasing [20]. Most likely this is a result of more infor-
mation becoming available regarding the similar prognosis
for the pregnant patient and the safety of surgery and che-
motherapy during pregnancy. In addition, termination of
the pregnancy has not been shown to improve survival,
and several reports suggest a trend toward shorter survival
[67–69].
Lactation and Breast Feeding
Chemotherapy when completed prior to delivery has been
shown to significantly decrease milk production, with one
report estimating that only 55% of women would be able to
successfully breast feed [20]. Additionally, chemotherapy
has been shown to be excreted into the breast milk. Neutro-
penia has been described in a nursing infant whose mother
wasreceivingcyclophosphamide[53,70].Therefore,preg-
nant breast cancer patients should be prepared to use for-
mula after delivery, and breast feeding is contraindicated in
women who are concomitantly receiving chemotherapy.
Hereditary Breast Cancer Syndromes
Women with strong family histories or known BRCA1 or
BRCA2 mutations are more likely to develop breast cancer
at a younger age, when pregnancy is more likely. There ap-
pears, however, to be a difference between BRCA1 and
BRCA2 mutations in relation to pregnancy. Antoniou et al.
[71] evaluated 457 mutation carriers who developed breast
cancer and compared them with 332 mutation carriers who
did not develop cancer. The protective effects of pregnancy
wereseenonlyamongcarrierswhowere40yearsold.In-
creasing age at first birth was associated with a higher risk
in BRCA2 carriers but not in BRCA1 carriers. Andrieu et al.
[72] also demonstrated a similar higher breast cancer risk
with later ages of parity in BRCA2 mutation carriers. Tryg-
gvadottir et al. [73] determined that an increasing number
of births decreased breast cancer risk in BRCA2
 women
Figure 1. Evaluation and management of breast cancer during pregnancy.
Abbreviations: DCIS, ductal carcinoma in situ; FAC, 5-fluorouracil, doxorubicin, and cyclophosphamide; MRI, magnetic
resonance imaging.
1244 Breast Cancer and Pregnancybut not in women with deleterious BRCA2 mutations. Jern-
ström et al. [74] demonstrated, in a case-control study, that
mutation carriers of both BRCA1 and BRCA2 had a higher
risk for breast cancer with a higher number of births. Culli-
nane et al. [75] reported on 1,260 pairs of women with
known BRCA1 and BRCA2 mutations and compared them
with matched nonmutation carriers. Women with a greater
number of children had a lower breast cancer risk if they
had a BRCA1 mutation (odds ratio [OR], 0.62; 95% confi-
dence interval [CI], 0.41–0.94), but BRCA2 mutation car-
riersappearedtohaveagreaterriskwithgreaterparity(OR,
1.53; 95% CI, 1.01–1.36). Also, in the 2-year period after a
birth, BRCA2 carriers had a trend for a higher risk for de-
veloping breast cancer (OR, 1.70; 95% CI, 0.97–3.0). Still,
Kotsopoulos et al. [76] reported on a multicenter trial in 11
different countries for 7,243 mutation carriers and matched
controlsshowingnosignificantdifferenceincancerratesin
BRCA mutation carriers when stratified for mutation, num-
berofpregnancies,orageatfirstpregnancy.Also,thenoted
protective role of an early first pregnancy did not appear to
confer the same protection in BRCA mutation carriers.
(Table 2).
CONCLUSION
The treatment of breast cancer during pregnancy should
proceed with a multidisciplinary approach and with direct
communication among the treating oncologists and the ob-
stetrician or maternal fetal specialists (Fig. 1). Increasingly
data are becoming available concerning the safety and effi-
cacy of standard treatments, and therefore these should be
initiated with minimal delay in the pregnant breast cancer
patient for optimal cancer control. Prospective evaluations
and long-term follow-up of children are necessary, but to
date there are no significant long-term health concerns
identified in children exposed to chemotherapy in utero. In
order to provide further information for this challenging
clinical situation, further collaborations between registries
and cancer centers is needed for long-term follow-up for
both the patient and the children.
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